Works by Papadopoulos, Kyriakos P

Results: 34
    1

    Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 6, p. 1065, doi. 10.1007/s00280-008-0811-x
    By:
    • Chia-Chi Lin;
    • Calvo, Emiliano;
    • Papadopoulos, Kyriakos P.;
    • Patnaik, Amita;
    • Sarantopoulos, John;
    • Mita, Alain C.;
    • Preston, Glenn G.;
    • Mita, Monica M.;
    • Rodon, Jordi;
    • Mays, Theresa;
    • I.-Tien Yeh;
    • O'Rourke, Pat;
    • Takimoto, Chris H.;
    • Dancey, Janet E.;
    • Chen, Helen;
    • Tolcher, Anthony W.
    Publication type:
    Article
    2

    Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.

    Published in:
    Neuro-Oncology Advances, 2023, v. 5, n. 1, p. 1, doi. 10.1093/noajnl/vdac183
    By:
    • Carneiro, Benedito A;
    • Papadopoulos, Kyriakos P;
    • Strickler, John H;
    • Lassman, Andrew B;
    • Waqar, Saiama N;
    • Chae, Young Kwang;
    • Patel, Jyoti D;
    • Shacham-Shmueli, Einat;
    • Kelly, Karen;
    • Khasraw, Mustafa;
    • Bestvina, Christine M;
    • Merrell, Ryan;
    • Huang, Kevin;
    • Atluri, Harisha;
    • Ansell, Peter;
    • Li, Rachel;
    • Jin, Janet;
    • Anderson, Mark G;
    • Reilly, Edward B;
    • Morrison-Thiele, Gladys
    Publication type:
    Article
    3
    4
    5
    6

    Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma

    Published in:
    Leukemia & Lymphoma, 2015, v. 56, n. 6, p. 1763, doi. 10.3109/10428194.2014.974040
    By:
    • Papadopoulos, Kyriakos P.;
    • Egile, Coumaran;
    • Ruiz-Soto, Rodrigo;
    • Jiang, Jason;
    • Shi, Weiliang;
    • Bentzien, Frauke;
    • Rasco, Drew;
    • Abrisqueta, Pau;
    • Vose, Julie M.;
    • Tabernero, Josep
    Publication type:
    Article
    7
    8
    9

    Lack of Meaningful Effect of Ridaforolimus on the Pharmacokinetics of Midazolam in Cancer Patients: Model Prediction and Clinical Confirmation.

    Published in:
    Journal of Clinical Pharmacology, 2014, v. 54, n. 11, p. 1256, doi. 10.1002/jcph.331
    By:
    • Stroh, Mark;
    • Talaty, Jennifer;
    • Sandhu, Punam;
    • McCrea, Jacqueline;
    • Patnaik, Amita;
    • Tolcher, Anthony;
    • Palcza, John;
    • Orford, Keith;
    • Breidinger, Sheila;
    • Narasimhan, Narayana;
    • Panebianco, Deborah;
    • Lush, Richard;
    • Papadopoulos, Kyriakos P.;
    • Wagner, John A.;
    • Trucksis, Michele;
    • Agrawal, Nancy
    Publication type:
    Article
    10

    Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.

    Published in:
    Neuro-Oncology, 2019, v. 21, n. 1, p. 106, doi. 10.1093/neuonc/noy091
    By:
    • Lassman, Andrew B;
    • Bent, Martin J van den;
    • Gan, Hui K;
    • Reardon, David A;
    • Kumthekar, Priya;
    • Butowski, Nicholas;
    • Lwin, Zarnie;
    • Mikkelsen, Tom;
    • Nabors, Louis B;
    • Papadopoulos, Kyriakos P;
    • Penas-Prado, Marta;
    • Simes, John;
    • Wheeler, Helen;
    • Walbert, Tobias;
    • Scott, Andrew M;
    • Gomez, Erica;
    • Lee, Ho-Jin;
    • Roberts-Rapp, Lisa;
    • Xiong, Hao;
    • Ansell, Peter J
    Publication type:
    Article
    11

    Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.

    Published in:
    International Journal of Cancer, 2021, v. 149, n. 2, p. 403, doi. 10.1002/ijc.33556
    By:
    • Tannir, Nizar M.;
    • Papadopoulos, Kyriakos P.;
    • Wong, Deborah J.;
    • Aljumaily, Raid;
    • Hung, Annie;
    • Afable, Manuel;
    • Kim, Jong Seok;
    • Ferry, David;
    • Drakaki, Alexandra;
    • Bendell, Johanna;
    • Naing, Aung
    Publication type:
    Article
    12

    Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.

    Published in:
    2018
    By:
    • Goss, Glenwood D.;
    • Vokes, Everett E.;
    • Gordon, Michael S.;
    • Gandhi, Leena;
    • Papadopoulos, Kyriakos P.;
    • Rasco, Drew W.;
    • Fischer, JuDee S.;
    • Chu, Katharine L.;
    • Ames, William W.;
    • Mittapalli, Rajendar K.;
    • Lee, Ho‐Jin;
    • Zeng, Jiewei;
    • Roberts‐Rapp, Lisa A.;
    • Loberg, Lise I.;
    • Ansell, Peter J.;
    • Reilly, Edward B.;
    • Ocampo, Christopher J.;
    • Holen, Kyle D.;
    • Tolcher, Anthony W.;
    • Lee, Ho-Jin
    Publication type:
    journal article
    13
    14
    15
    16
    17
    18
    19
    20

    Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.

    Published in:
    Journal of Hematology & Oncology, 2014, v. 7, n. 1, p. 3, doi. 10.1186/1756-8722-7-1
    By:
    • Rhoda Molife, L.;
    • Li Yan;
    • Vitfell-Rasmussen, Joanna;
    • Zernhelt, Adriane M.;
    • Sullivan, Daniel M.;
    • Cassier, Philippe A.;
    • Eric Chen;
    • Biondo, Andrea;
    • Tetteh, Ernestina;
    • Siu, Lillian L.;
    • Patnaik, Amita;
    • Papadopoulos, Kyriakos P.;
    • De Bono, Johann S.;
    • Tolcher, Anthony W.;
    • Minton, Susan
    Publication type:
    Article
    21

    Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.

    Published in:
    British Journal of Haematology, 2016, v. 173, n. 6, p. 884, doi. 10.1111/bjh.14014
    By:
    • Lee, Susan J.;
    • Levitsky, Konstantin;
    • Parlati, Francesco;
    • Bennett, Mark K.;
    • Arastu‐Kapur, Shirin;
    • Kellerman, Lois;
    • Woo, Tina F.;
    • Wong, Alvin F.;
    • Papadopoulos, Kyriakos P.;
    • Niesvizky, Ruben;
    • Badros, Ashraf Z.;
    • Vij, Ravi;
    • Jagannath, Sundar;
    • Siegel, David;
    • Wang, Michael;
    • Ahmann, Gregory J.;
    • Kirk, Christopher J.
    Publication type:
    Article
    22
    23

    Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).

    Published in:
    Science Signaling, 2018, v. 11, n. 551, p. 1, doi. 10.1126/scisignal.aat9773
    By:
    • Cocco, Emiliano;
    • Javier Carmona, F.;
    • Razavi, Pedram;
    • Won, Helen H.;
    • Cai, Yanyan;
    • Rossi, Valentina;
    • Chan, Carmen;
    • Cownie, James;
    • Soong, Joanne;
    • Toska, Eneda;
    • Shifman, Sophie G.;
    • Sarotto, Ivana;
    • Savas, Peter;
    • Wick, Michael J.;
    • Papadopoulos, Kyriakos P.;
    • Moriarty, Alyssa;
    • Cutler, Richard E.;
    • Avogadri-Connors, Francesca;
    • Lalani, Alshad S.;
    • Bryce, Richard P.
    Publication type:
    Article
    24
    25
    26

    Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony‐Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

    Published in:
    Oncologist, 2021, v. 26, n. 9, p. e1508, doi. 10.1002/onco.13810
    By:
    • Babiker, Hani;
    • Brana, Irene;
    • Mahadevan, Daruka;
    • Owonikoko, Taofeek;
    • Calvo, Emiliano;
    • Rischin, Danny;
    • Moreno, Victor;
    • Papadopoulos, Kyriakos P.;
    • Crittenden, Marka;
    • Formenti, Silvia;
    • Giralt, Jordi;
    • Garrido, Pilar;
    • Soria, Ainara;
    • Hervás‐Morón, Asunción;
    • Mohan, Kosalai Kal;
    • Fury, Matthew;
    • Lowy, Israel;
    • Mathias, Melissa;
    • Feng, Minjie;
    • Li, Jingjin
    Publication type:
    Article
    27

    A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.

    Published in:
    Oncologist, 2018, v. 23, n. 6, p. 658, doi. 10.1634/theoncologist.2017-0325
    By:
    • Tolcher, Anthony;
    • Flaherty, Keith;
    • Shapiro, Geoffrey I.;
    • Berlin, Jordan;
    • Witzig, Thomas;
    • Habermann, Thomas;
    • Bullock, Andrea;
    • Rock, Edwin;
    • Elekes, Agnes;
    • Lin, Chester;
    • Kostic, Dusan;
    • Ohi, Naoto;
    • Rasco, Drew;
    • Papadopoulos, Kyriakos P.;
    • Patnaik, Amita;
    • Smith, Lon;
    • Cote, Gregory M.
    Publication type:
    Article
    28
    29

    Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 1, p. 182, doi. 10.1007/s10637-020-01000-6
    By:
    • Hecht, J. Randolph;
    • Papadopoulos, Kyriakos P.;
    • Falchook, Gerald S.;
    • Patel, Manish R.;
    • Infante, Jeffrey R.;
    • Aljumaily, Raid;
    • Wong, Deborah J.;
    • Autio, Karen A.;
    • Wainberg, Zev A.;
    • Bauer, Todd M.;
    • Javle, Milind;
    • Pant, Shubham;
    • Bendell, Johanna;
    • Hung, Annie;
    • Ratti, Navneet;
    • VanVlasselaer, Peter;
    • Verma, Rakesh;
    • Leveque, Joseph;
    • Rao, Sujata;
    • Oft, Martin
    Publication type:
    Article
    30
    31
    32
    33
    34